Friday, 19 Jul 2019

You are here

Post-Approval Exploratory Trials with Pregabalin Often Fail

A systematic review of 238 pregabalin (Lyrica) trials for nonapproved indications shows that nearly two-thirds yielded uncertain evidence of efficacy, thereby questioning the off-label use or endorsement in clinical practice guidelines.

Pregabalin was FDA approved in 2004 for neuropathic pain and in 2007 for fibromyalgia.  In October 2017 the FDA approved Lyrica CR (an extended-release pregabalin for neuropathic pain conditions). Pregabalin is expected to go off patent in December 2018 and it's sales are expected to drop from $5 billion in 2018 to roughly $3 billion in 2019.

This review set out to establish the findings of post-approval exploratory and confirmatory postapproval trials (often done in off-label indications) with pregabalin. 

They found 238 trials assessing the efficacy of pregabalin in 33 indications; 5  of whom later received European Medicines Agency and/or US FDA marketing approval.

For new indications 67% (22 of 33), trials failed to generate positive proof of efficacy and generally these were not changed over time or by repeat studies.

These findings question the practice of (often smaller) exploratory and confirmatory trials on new or off-label indications.  Stronger oversight by regulatory agencies and manufacturers should be encouraged to avoid the risk of inappropriate promotion and use of newly approve drugs. 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

A Potential Biomarker for Chronic Fatigue Syndrome Patients

Myalgic encephalomyelitis/chronic fatigue syndrome affects at least 2 million people in the United States and bears tremendous overlap with fibromyalgia - both being difficult to diagnosis because the symptom complex is often unrecognized and these conditions have no biomarker test. 

NIH Conference Review of Chronic Fatigue Syndrome

The current issue of JAMA reviews recent advances on chronic fatigue syndrome, also known as myalgic encephalomyelitis/(ME/CFS), based on a 2-day conference held at the NIH in an April 2019. The NIH 2-day conference reviewed recent progress and new research in several areas described below.

Study Looks at Opioid Use After Knee Surgery

A small study looked at whether reducing the number of opioid tablets prescribed after knee surgery would reduce postoperative use and if preoperative opioid-use education would reduce it even more.

Gabapentinoid Drugs Overuse and Misuse

A recent article in JAMA by Drs. Goodman and Brett reviews the increasing off label use of gabapentinoid drugs, originally developed as antiseizure drugs that are now increasingly prescribed for painful conditions.

Pilot Study Targets Insulin Resistence in Fibromyalgia

An unusual pilot study has shown that insulin resistence (IR), assessed by Hgb-A1c levels, was more prevalent in fibromyalgia (FM) patients compared to non-diabetic controls and that when FM patients were given metformin, half had complete resolution of their pain.